AR and neoplasm: Based on the dynamic changes in the androgen receptor (AR) gene and AR-V7 in circulating tumor cells, researchers have established a method to predict sensitivity to chemotherapy and endocrine therapy in metastatic castration-resistant prostate cancer (mCRPC) [274].